Role of PET/CT with 124I for dosimetry of thyroid carcinoma before radioisotopic treatment
- Conditions
- thyroid carcinomaMedDRA version: 14.1Level: LLTClassification code 10043655Term: Thryoid neoplasiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2011-001386-41-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
?Patients with diagnosis of thyroid carcinoma, already operated by radical tyroidectomy, with lung or bone metastases showing radioiodine uptake; those patients are treated with radiomethabolic therapy using 131I
?age superior or egual to 18years
?male and female
?signed informed consent
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
?pregnancy
?breastfeeding
?patients in emergency situations
?patients of unsound mind
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method